Addressing Quality of Life, Clinical Outcomes, and Mechanisms in Uncontrolled Asthma Following the DASH Dietary Pattern

Description

The goal of the ALOHA trial is to investigate the efficacy of improved diet quality following a DASH behavioral intervention that has shown promising results in adults with uncontrolled asthma. DASH stands for Dietary Approaches to Stop Hypertension. This healthy diet is known to help people with high blood pressure manage their health. But physicians do not know if the DASH diet can also benefit patients with uncontrolled asthma. Researchers in the ALOHA study are trying to find out the answer to this important question. Researchers at UIC are studying how 2 asthma care programs compare in terms of helping adults with uncontrolled asthma to improve their quality of life. Researchers also want to learn what might explain the differences in patient outcomes that they may see between the 2 programs. The primary outcome will be asthma-specific quality of life. If the DASH behavioral intervention is found to benefit people with uncontrolled asthma, it would provide a practical, safe, and acceptable public-health intervention in the form of dietary modification to reduce the burden of asthma.

Conditions

Asthma

Study Overview

Study Details

Study overview

The goal of the ALOHA trial is to investigate the efficacy of improved diet quality following a DASH behavioral intervention that has shown promising results in adults with uncontrolled asthma. DASH stands for Dietary Approaches to Stop Hypertension. This healthy diet is known to help people with high blood pressure manage their health. But physicians do not know if the DASH diet can also benefit patients with uncontrolled asthma. Researchers in the ALOHA study are trying to find out the answer to this important question. Researchers at UIC are studying how 2 asthma care programs compare in terms of helping adults with uncontrolled asthma to improve their quality of life. Researchers also want to learn what might explain the differences in patient outcomes that they may see between the 2 programs. The primary outcome will be asthma-specific quality of life. If the DASH behavioral intervention is found to benefit people with uncontrolled asthma, it would provide a practical, safe, and acceptable public-health intervention in the form of dietary modification to reduce the burden of asthma.

The ALOHA Trial: Addressing Quality of Life, Clinical Outcomes, and Mechanisms in Uncontrolled Asthma Following the DASH Dietary Pattern

Addressing Quality of Life, Clinical Outcomes, and Mechanisms in Uncontrolled Asthma Following the DASH Dietary Pattern

Condition
Asthma
Intervention / Treatment

-

Contacts and Locations

Chicago

Department of Medicine, Chicago, Illinois, United States, 60608

Chicago

UIC CCTS Clinical Research Center, Chicago, Illinois, United States, 60608

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years or older at study enrollment
  • * Diagnosis of asthma with currently prescribed controller therapy (i.e., Step 2 or above) according to the 2020 asthma guideline update (EPR4)
  • * Uncontrolled asthma on study screening based on Asthma Control Test (ACT) scores \<20
  • * Being able and willing to provide written informed consent and HIPAA authorization
  • * Inability to speak, read or understand English sufficiently to provide valid informed consent
  • * Primary diagnosis of COPD (emphysema or chronic bronchitis)
  • * Previous cardiovascular disease: coronary heart disease (myocardial infarction, angina pectoris, percutaneous coronary intervention, coronary artery bypass graft surgery), cerebrovascular disease (stroke, transient ischemic attack), peripheral vascular disease, heart failure, or aortic aneurysm
  • * Diabetes (other than during pregnancy)
  • * Diagnosis of cancer (other than non-melanoma skin cancer) within the past year and/or actively receiving cancer treatment
  • * Inflammatory bowel disease, colostomy, malabsorption, or major gastrointestinal resection
  • * Diagnosis of bipolar or psychotic disorder
  • * Hospitalization for psychological or emotional problems within the last 2 years
  • * Cognitive impairment based on the Callahan 6-item screener67
  • * Terminal illness or in hospice or long-term care
  • * Current diet of good quality (DASH concordance index ≥6 out of 9 total)
  • * Current/planned participation in another structured program that overtly focuses on diet and nutrition
  • * On special diet that precludes changes adherent to the DASH dietary pattern or otherwise unwillingness to modify current diet
  • * Current use of prescription or non-prescription weight-loss products and unwillingness to stop taking them for the duration of the study
  • * Underweight per body mass index (BMI) below 18.5 kg/m2 based on measured height and weight at study enrollment
  • * Actively attempting to lose weight or weight change \>15 lbs during prior 3 months
  • * Active alcohol or substance use disorder (including prescription drugs) based on the CAGE Questionnaire Adapted to Include Drugs (CAGE-AID)68
  • * Current within the past 6-months or former smoker (more than 20-packs of cigarettes in the lifetime, or current smoker)
  • * Current or planned pregnancy or currently lactating
  • * Planning to move out of the area during the study period
  • * Participation in another clinical trial or investigational treatment study
  • * Family/household member of an already enrolled participant or of a study team member
  • * Investigator discretion for clinical safety or protocol adherence reasons

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Illinois at Chicago,

Jun Ma, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Illinois at Chicago

Study Record Dates

2026-09-01